Friday, December 9, 2022 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

Rigel Pharmaceuticals inflated its share price by issuing false and misleading information about clinical trials and prospects for its R788 drug, shareholders say in San Francisco Federal Court. Shareholders say share price tripled after the allegedly misleading press release.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.